The study was funded by the NIH, the Skin Disease Research Center, the Pennsylvania Department of Health, the Edwin and Fannie Gray Hall Center for Human Appearance at University of Pennsylvania Medical Center, the American Skin Association, the Dermatology Foundation, and L'Oreal.
Cotsarelis and one of his co-authors are co-inventors of a patent owned by the University of Pennsylvania describing the PGD2 pathway as a target for inhibiting hair loss, among other claims. One of the other study authors is an inventor of a patent owned by the Gillette Corporation to use PGD2 to inhibit hair growth. One of the authors works for Merck and another works for Allergan.
Cotsarelis and one of his co-authors are co-inventors of a patent owned by the University of Pennsylvania describing the PGD2 pathway as a target for inhibiting hair loss, among other claims. One of the other study authors is an inventor of a patent owned by the Gillette Corporation to use PGD2 to inhibit hair growth. One of the authors works for Merck and another works for Allergan.
Comment